The epigenetic regulator Histone Deacetylase 1 promotes transcription of a core neurogenic programme in zebrafish embryos
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2164
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The epigenetic regulator Histone Deacetylase 1 promotes transcription of a core neurogenic programme in zebrafish embryos ; volume:12 ; number:1 ; day:12 ; month:1 ; year:2011 ; pages:1-18 ; date:12.2011
BMC genomics ; 12, Heft 1 (12.1.2011), 1-18, 12.2011
- Urheber
-
Harrison, Michael RM
- Beteiligte Personen und Organisationen
-
Georgiou, Aristophanes S.
Spaink, Herman P.
Cunliffe, Vincent T.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2164-12-24
- URN
-
urn:nbn:de:1111-2016072830705
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Harrison, Michael RM
- Georgiou, Aristophanes S.
- Spaink, Herman P.
- Cunliffe, Vincent T.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Histone deacetylase 6 in cancer
Sodium Butyrate, a Histone Deacetylase Inhibitor, Exhibits Neuroprotective/Neurogenic Effects in a Rat Model of Neonatal Hypoxia-Ischemia
Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
Regulatory mechanisms of histone deacetylase 2 Sumoylation
Role of histone deacetylase 11 in neuroblastoma
Limited proteolysis of human histone deacetylase 1
Development of class IIa histone deacetylase inhibitors
Dendritic cell development requires histone deacetylase activity
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
Nitric oxide affects histone acetylation by inhibiting histone deacetylase activity in Arabidopsis
Histone deacetylase inhibitors: clinical implications for hematological malignancies
Nanomicelles potentiate histone deacetylase inhibitor efficacy in vitro
Histone deacetylase 6 in cancer
Sodium Butyrate, a Histone Deacetylase Inhibitor, Exhibits Neuroprotective/Neurogenic Effects in a Rat Model of Neonatal Hypoxia-Ischemia
Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
Regulatory mechanisms of histone deacetylase 2 Sumoylation
Role of histone deacetylase 11 in neuroblastoma
Limited proteolysis of human histone deacetylase 1
Development of class IIa histone deacetylase inhibitors
Dendritic cell development requires histone deacetylase activity
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
Nitric oxide affects histone acetylation by inhibiting histone deacetylase activity in Arabidopsis
Histone deacetylase inhibitors: clinical implications for hematological malignancies
Nanomicelles potentiate histone deacetylase inhibitor efficacy in vitro
Histone deacetylase 6 in cancer
Sodium Butyrate, a Histone Deacetylase Inhibitor, Exhibits Neuroprotective/Neurogenic Effects in a Rat Model of Neonatal Hypoxia-Ischemia
Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
Regulatory mechanisms of histone deacetylase 2 Sumoylation
Role of histone deacetylase 11 in neuroblastoma
Limited proteolysis of human histone deacetylase 1
Development of class IIa histone deacetylase inhibitors
Dendritic cell development requires histone deacetylase activity
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
Nitric oxide affects histone acetylation by inhibiting histone deacetylase activity in Arabidopsis
Histone deacetylase inhibitors: clinical implications for hematological malignancies